These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome. Saunders RE; Perkins SJ Semin Thromb Hemost; 2006 Mar; 32(2):160-8. PubMed ID: 16575691 [TBL] [Abstract][Full Text] [Related]
24. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264 [TBL] [Abstract][Full Text] [Related]
25. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Sullivan M; Rybicki LA; Winter A; Hoffmann MM; Reiermann S; Linke H; Arbeiter K; Patzer L; Budde K; Hoppe B; Zeier M; Lhotta K; Bock A; Wiech T; Gaspert A; Fehr T; Woznowski M; Berisha G; Malinoc A; Goek ON; Eng C; Neumann HP Ann Hum Genet; 2011 Nov; 75(6):639-47. PubMed ID: 21906045 [TBL] [Abstract][Full Text] [Related]
26. The role of defective complement control in hemolytic uremic syndrome. Zipfel PF; Misselwitz J; Licht C; Skerka C Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689 [TBL] [Abstract][Full Text] [Related]
27. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Noris M; Remuzzi G Clin Exp Immunol; 2008 Feb; 151(2):199-209. PubMed ID: 18070148 [TBL] [Abstract][Full Text] [Related]
28. Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMD. Goodship TH Kidney Int; 2006 Jul; 70(1):12-3. PubMed ID: 16810287 [TBL] [Abstract][Full Text] [Related]
29. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation. Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771 [TBL] [Abstract][Full Text] [Related]
30. Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome. Jung S; Kang ES; Ki CS; Kim DW; Paik KH; Chang YS J Clin Apher; 2011; 26(3):162-5. PubMed ID: 21322001 [TBL] [Abstract][Full Text] [Related]
31. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644 [TBL] [Abstract][Full Text] [Related]
32. Complement factor H and the haemolytic uraemic syndrome. Taylor CM Lancet; 2001 Oct; 358(9289):1200-2. PubMed ID: 11675053 [No Abstract] [Full Text] [Related]
33. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Hirt-Minkowski P; Schaub S; Mayr M; Schifferli JA; Dickenmann M; Frémeaux-Bacchi V; Steiger J Nephrol Dial Transplant; 2009 Nov; 24(11):3548-51. PubMed ID: 19633317 [TBL] [Abstract][Full Text] [Related]
38. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Noris M; Remuzzi G Nat Clin Pract Nephrol; 2005 Nov; 1(1):2-3. PubMed ID: 16932353 [No Abstract] [Full Text] [Related]